Here are five takeaways:
1. Stryker first acquired 92 percent of Vexim’s share capital and 91 percent of the company’s voting rights from November to December 2017. Later in December 2017, Stryker acquired an additional 300,016 shares, crossing the 95 percent threshold.
2. Currently Stryker holds more than 8.7 million shares and 95.14 percent of the company’s voting rights.
3. In the coming weeks, Stryker intends to file a public-buy offer for all outstanding shares for $24.79 per share. This will be followed by a squeeze-out of all remaining non-tendered shares.
4. Stryker anticipates the squeeze-out to take place in the second quarter of 2018.
5. Vexim shares will remain suspended from trading until Stryker’s filing offers.
More articles on devices and implants:
5 things to know about Stryker CEO Kevin Lobo
Dr. Vik Kapoor shares initial data on Medovex’s DenerveX System: 4 points
Enrollment begins for study on Orthofix’s RCStim device for rotator cuff repair — 5 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
